Response to R. L. Nevin “Considerations in the repurposing of mefloquine for prevention and treatment of osteoporosis”

The authors would like to thank the reader for his interest in our article and his insightful feedback [1]. All of the points raised are important to take into consideration when looking at the possibility of using mefloquine to treat bone loss in aging. As correctly indicated by Dr. Nevin, the other members of the quinine family of drugs, but not mefloquine, have been used in humans to prevent skeletal complications. Our study was meant to be more of a proof of concept study based on the previous findings that other chloroquines effect bone mass.

Source: Bone - July 9, 2018 Category: Orthopaedics Authors: Hannah M. Davis, Rafael Pacheco-Costa, Lilian I. Plotkin Tags: Correspondence Source Type: research